Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

l benefit response (CBR), time to progression (TTP), duration of response (DOR), progression-free survival, and best ORR throughout the study. Patients enrolled in the trial will receive carfilzomib twice weekly for three weeks every 28 days.

"Based on promising laboratory and clinical data, we believe that carfilzomib holds promise in treating patients with multiple myeloma, including those for whom other treatments have failed," said Sundar Jagannath, M.D., Saint Vincent's Comprehensive Cancer Center, where the first patient was enrolled. "We are excited to bring this compound into the MMRC as a critical step in bringing this new treatment to patients."

In the coming weeks, the MMRC and Proteolix will also begin enrolling an open-label, single-arm, Phase 2 study of carfilzomib in patients with relapsed multiple myeloma, who will be stratified by bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) history.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for the unique N-terminal threonine active sites within the proteasome. Carfilzomib is similar to bortezomib in that it is a potent inhibitor of the proteasome chymotrypsin- like activity, but unlike bortezomib, carfilzomib has shown minimal cross- reactivity with the other catalytic sites within the proteasome or across other protease classes. Phase 1 clinical studies confirmed that patients who have relapsed or progressed following multiple therapies can still achieve durable anti-tumor responses with carfilzomib. In addition to the two Phase 2 single-agent trials in myeloma and ongoing studies in lymphoma, a clinical trial in solid tumors and a trial exploring carfilzomib in combination with an FDA-approved agent will be initiated by the end of the year.

"The Phase 1 data consistently demonstrate carfilzomib anti-tumor activity in myeloma patients who have failed multiple lines of therapy,
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ov.24/PRNewswire/-- EisaiInc.andPfizerIncannounce...acceptedforreviewEisai,sNewDrugApplication(NDA)for...ease)tabletsforthetreatmentofmoderatetosevereAlzhe...ains23mgofdonepezilHClinanextendedrelease,matrix-t...leaseofthedrug.TheNDAisbasedonahead-to-headclinica...
(Date:11/24/2009)...swire-FirstCall/--ThoratecCorporation(Nasdaq: THOR...supporttherapiestosave,supportandrestorefailinghea...ualPiperJaffrayHealthCareConferenceonTuesday,Decem...chieffinancialofficer,willprovideanupdateonthecomp...m.,PacificStandardTime). ,, Thepresentationwill...
(Date:11/24/2009)...re/--ZargisMedicalCorp.,asubsidiaryofSpeedusCorp.(...arch(NYSE: SI ),todayannouncedthatitsZargisCardios...BS, TheEarlyShow duringasegmentinwhichMarkJannot,t...ningproductsfromthepublication,s2009"BestofWhat,sN...evisionmorningnewstalkshowbroadcastbyCBSfromNewYor...
Breaking Medicine Technology:FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3MedAssurant to Support AHIPs Research Capabilities 57024 1MedAssurant to Support AHIPs Research Capabilities 57024 2Thoratec Presentation at UBS Conference to be Webcast 57022 1Enobia Announces Positive Clinical Results With ENB 0040 a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia 4996 1Enobia Announces Positive Clinical Results With ENB 0040 a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia 4996 2Enobia Announces Positive Clinical Results With ENB 0040 a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia 4996 3
...INGSTON, N.J.--(BUSINESS WIRE)--Jun 25, 2007 - Col...today that an interim,analysis of a pregnancy stud...erone gel) to compounded intramuscular progesteron...l be published in,Fertility and Sterility, the jou...cine (ASRM)., This ongoing prospective randomized ...
...YMOUTH MEETING, Pa., June 25, 2007 /PRNewswire-Fir...t data from a preclinical,study of trodusquemine (...ted during the American Diabetes Association (ADA)...IL. Dr. Kristen Lantz,Genaera research scientist ...rodusquemine is a Multiple Pathway Inhibitor that,...
Other Medicine Technology:Interim Analysis of Crinone Pregnancy Study to Be Published in,American Society for Reproductive Medicine Journal 2Interim Analysis of Crinone Pregnancy Study to Be Published in,American Society for Reproductive Medicine Journal 3Interim Analysis of Crinone Pregnancy Study to Be Published in,American Society for Reproductive Medicine Journal 4Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 2Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 3Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 4
(Date:11/25/2009)...Minn.,Nov.25/PRNewswire-USNewswire/--Whenmostpeopl...ropractorcanalsogivepatientsthehelptheyneed.TMJsta...jaw(mandible)contacts/connectswithyourskull(tempor...TMJdysfunctionarepainwithchewing,clickingorpopping...functionincluding:headaches,fatigue,sleepdisturban...
(Date:11/25/2009)...ACH,Calif.,Nov.25/PRNewswire/--Thanksgivingmealswi...nthegreaterLongBeachareathankstoFaithInAction/Volu...atHome(IAH),adivisionofSCANHealthPlan.Formorethan1...nteerstodeliverwarmThanksgivingmealstoseniorsinnee...Angelesandsurroundingcities. ,, "Ourwarmholiday...
(Date:11/25/2009)...rvivors of testicular cancer who were treated with... effects, including neurological side effects and ...ted with chemotherapy, according to a new study pu...National Cancer Institute . , Marianne Brydy, M....rsity Hospital, in Bergen, Norway, and colleagues ...
(Date:11/25/2009)...eady used to fight rheumatoid arthritis, could hel... , WEDNESDAY, Nov. 25 (HealthDay News) -- A drug... rheumatoid arthritis now also shows some promise ...abetes. , The drug, rituximab (Rituxan), helped..., even though the disease had destroyed some of th...
(Date:11/25/2009)...K,Nov.25/PRNewswire/-- MISSIONSkincare ®ispro...St.Jude.AspartofGNC,sannualSt.Jude ThanksandGiving...ncare,s new SUPER-C(TM)LipBalm willbedonatedtoSt...omakea$1,$5or$10donationatcheckoutatoneoftheir5,00...an$1millionforSt.Judeduringtheir2009 ThanksandGivi...
Breaking Medicine News(10 mins):Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2
...RG, S.C., Feb. 10 Zeus, Inc. is pleased to introd...live and accessible via http://www.zeusinc.com . ... site is a user-friendly resource for comprehensiv...t of information into four categories listed on th...
..., Ill., Feb. 10 A prestigious panel of pain-manag...ty (APS) www.ampainsoc.org and the American Acad...t comprehensive clinical practice guideline to ass...rent issue of The Journal of Pain , www.jpain.or...
... Cambridge Healthtech Media Group,...ounced the launch of a new website devoted to excl... --www.ecliniqua.com. , N...website devoted to exclusive coverage of the clini...
...ts at the Institute for Myeloma and Bone Cancer Re...ould explain how blood vessels form within tumors....vered a new way that cancers orchestrate the produ...by tumor cells in multiple myeloma, a common form ...
...INGTON, Del., Feb. 10 Four western New York hospi...ing evidence-based therapy and,better communicatio... patient,deaths by 19 percent for up to one year a...Mortality in Patients,with Acute Coronary Syndrome...
...ARD, Calif., Feb. 10 Arete Therapeutics Inc. toda... trial for AR9281, an orally-,administered soluble...d for,the treatment of type 2 diabetes. S-EH is an... "Our AR9281 Phase II clinical trial program break...
Other Medicine News:Health News:New Guidelines for Prescribing Opioid Pain Drugs Published 2Health News:Cambridge Healthtech Media Group Launches Clinical Trials Web Site 2Health News:Cambridge Healthtech Media Group Launches Clinical Trials Web Site 3Health News:Researchers Identify Novel Mechanism That Make Cancer Tumors Grow 2Health News:Emergency Treatment Strategies, Better Communication Among Health Care Workers Reduce Heart Attack Patient Deaths by 19 Percent, Says AHJ Published Study 2Health News:Emergency Treatment Strategies, Better Communication Among Health Care Workers Reduce Heart Attack Patient Deaths by 19 Percent, Says AHJ Published Study 3Health News:Emergency Treatment Strategies, Better Communication Among Health Care Workers Reduce Heart Attack Patient Deaths by 19 Percent, Says AHJ Published Study 4Health News:Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes 2Health News:Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes 3
RGP OrthoK Lenses
... rigid gas permeable contact lenses used for corne...corrects nearsightedness (myopia). The patient wea... them upon wakening. During the day, nearsightedne...RT and Quadra RG contact lenses apply slight press...
...ware of the High Prevalence of Sleep Disordered Br...t Population?, , As Prevalent as Diabetes, with Va...OSA), the most common form of SDB, affects an esti...y 5% of the OSA patients have been diagnosed, leav...
... SP-9000 is exactly the same as the model SP-8800 ...separate Pachy mode. This mode has its own fixatio...directions. It allows you to select an area on the...t-in software to calculate averages of multiple re...
Medicine Products: